Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study.

e12087 Background: Despite being chemosensetive, the majority of triple-negative breast cancer (TNBC) patients recur. The primary study objectives of the current phase III trial were to compare disease free survival (DFS), and overall survival (OS) for TNBC after adjuvant chemotherapy, who underwent maintenance metronomic chemotherapy versus no maintenance therapy. Methods: TNBCpatients were eligible for enrolment if they had TNM stages II-III and fit with our inclusion criteria. For their adjuvant chemotherapy, patients were assigned to either; Group1; 3cycles FEC-100 then 3 cycles docetaxel, carboplatin, followed by maintenance metronomic chemotherapy for 1 year, and group2; 3cycles FEC-100 then 3cycles docetaxel. Results: Between November 2008 and December 2014, 158 patients (78 group1, and 80 group2) were enrolled. The mean age was 46 years. The median performance status was 0. The median DFS for group 1, 2 were 26 months, 24 months respectively. The median OS for group 1, 2 were 34 months, 28 months ...